Lykos Therapeutics may have shed three-quarters of its staff in the wake of the FDA's rejection of its MDMA candidate for ...

In a short statement Friday, Lykos Therapeutics expressed optimism about a recent meeting with the regulator to discuss next ...

Lykos Therapeutics said it had a “productive” meeting with the FDA to discuss a path forward for its recently rejected PTSD ...

The fallout from the FDA's recent decision not to approve Lykos Therapeutics' psychedelic treatment has spread to its senior management, with chief executive Amy Emerson stepping down. Emerson has ...

Recommended Reading In tone-setting verdict, FDA rejects MDMA as a therapy aid for PTSD The CEO of Lykos Therapeutics will step down after the company’s efforts to win a milestone approval for ...

(Reuters) - Lykos Therapeutics said on Thursday longtime CEO Amy Emerson would step down from the role, in the latest shakeup after the U.S. health regulator declined to approve its MDMA-based ...

Lykos Therapeutics is slashing around 75% of its staff following the FDA's decision not to approve its MDMA-assisted therapy for post-traumatic stress disorder (PTSD) last week, with founder Rick ...

The FDA has previously acknowledged its therapeutic potential, granting a new drug application, submitted by Lykos Therapeutics (formerly MAPS Public Benefit Corporation), priority review for ...

The US Food and Drug Administration (FDA) was examining the psychedelic drug made by Lykos Therapeutics to treat the mental health disorder in combination with talk therapy. The drug maker said ...

An FDA advisory panel voted against recommending the use of MDMA in PTSD therapy. The rejection of Lykos Therapeutics' treatment hurt stocks of firms with similar therapies in development.

The recent 10% drop in Lykos Metals Limited's ( ASX:LYK ) stock could come as a blow to insiders who purchased ...

The recent 10% drop in Lykos Metals Limited's ( ASX:LYK ) stock could come as a blow to insiders who purchased ...